Navigation Links
Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
Date:2/15/2012

LONDON, February 15, 2012 /PRNewswire/ --

Senior representatives from leading pharmaceutical companies including Roche Diagnostics, Lonza, Abbott, F. Hoffman-La-Roche LTD and Novartis MIT will meet at the Pharma Qbd Forum in Berlin, Germany on 24th-25th April 2012 to share their expert knowledge on how Quality by Design can be implemented in pharmaceutical development.

One of the main points of discussion will be the findings of the Merck Serono case study and how the lessons learned from this FDA Pilot Programme can shape the way for QbD projects in Europe and abroad. This session will be led by Pascal Valax, Group Head, Biotech Process Sciences, Merck Serono SA.

Speakers include:

  • Dr. John R Donaubauer, Director, Scientific Affairs Development Sciences Process R&D - Abbott
  • Dr.Richard Lakerveld, Associate - Novartis-MIT Center for Continuous Manufacturing
  • Serj Vartanian, Head of Global Quality Systems MBB - Baxter Healthcare Corporation
  • Dr. Gawayne Mahboubian-Jones, Program head - Excellence in Science and Design - Philip Morris International
  • Dr.Paul Stonestreet, Global Drug Substance Project Co-ordinator, Small Molecule Technical Development - F.Hoffman-La-Roche Ltd
  • Dr. Dirk Pamperin, VP R&D - Synthon Pharmaceuticals
  • Dr. Alessandro Butte, Head of DSP - Lonza
  • Sarah Mercier, Scientist USP - Crucell Holland BV
  • Dr. John Crowley, Head of Cell Culture Development - Lonza Biologics
  • Dr. Andreas Schneider, Vice President Life Science Alliances - Roche Diagnostics
  • Prof. Gary Montague, Professor of Bioprocess Control - Newcastle University
  • Dr. Mel Koch, Executive Director - CPAC Centre for Process and Analytical Control (University of Washington)
  • Prof. Mathieu Streefland, Professor Bioprocess Engineering - Wageningen University
  • Prof. Jose Cardoso de Menezes, Department of BioEngineering - Institute of Biotechnology & Bioengineering

Conference topics include:

  • Building quality earlier in the process
  • Improving process understanding
  • Successfully defining criticality
  • Defining continuous verification and the expanded change protocol
  • Lifecycle strategies for biopharmaceutical QbD
  • Implementing continuous manufacturing with QbD to reduce production timelines
  • Translating established development practice into QbD

To view the complete programme, speakers and topics visit http://www.pharmaqbdforum.com

For all press enquiries, email sarah.brzezicki@wtgevents.com or telephone +44(0)207-202-7727.



'/>"/>
SOURCE World Trade Group Conferences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and VIWA Pharmaceutical Company Today Jointly Announce the Signing of a Memorandum of Understanding (MOU) Setting Out Their Intention to Establish a Joint Venture to Develop and Register a Range of Branded Generic Medicines
2. HIFU All Hype? Understanding This Non-FDA-Approved Prostate Cancer Treatment
3. Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke
4. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
5. American Pain Foundation Launches New Educational Campaign, "Explain Your Pain," to Help Hispanic Americans Better Understand Chronic Pain and Pain Management
6. FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads
7. Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits
8. Ground Breaking Findings on Understanding Cancer Published in the Current Issue of Science
9. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
10. Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose
11. Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):